PART III MARKETING ORGANISMS
Requirement for consent to market14.
The cases and circumstances prescribed for the purposes of section 111(1)(a) of the Act in relation to marketing genetically modified organisms are all cases and circumstances in relation to the marketing of genetically modified organisms.
Exempt activities15.
F1(1)
The cases and circumstances prescribed for the purposes of F2section 111(7) of the Act in which persons are exempt from the requirements of F3... section 111(1)(a) of the Act (to obtain consent) F4... insofar as F5it relates to marketing genetically modified organisms, are all cases and circumstances in which–
(a)
(b)
genetically modified micro-organisms are made available for activities regulated under the Contained Use Directive (including culture collections);
(c)
genetically modified organisms other than micro-organisms referred to in paragraph (b) are made available to be used exclusively for activities where appropriate stringent containment measures based on the same principles of containment as laid down in the Contained Use Directive are used to limit their contact with and to provide a high level of safety for the general population and the environment;
(d)
genetically modified organisms are made available to be used exclusively for deliberate releases complying with the requirements laid down in Part II;
(e)
a genetically modified organism authorised under Regulation 2309/93 F9or F10Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency is marketed; F11and
F12(f)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F13(g)
genetically modified food or feed authorised under the Food and Feed Regulation is marketed.
F14(2)
In paragraph (1)(e), “Regulation 2309/93” means Council Regulation (EEC) No 2309/93 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products, as it had effect before it was repealed by Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
Applications for consent to market16.
(1)
An application for a consent to market genetically modified organisms under section 111(1) of the Act must be made in writing to the Scottish Ministers.
(2)
An application for a consent to market genetically modified organisms which is not an application for renewal of consent must contain the following information:–
F15(a)
the information prescribed in Part 2 of schedule 2, where the application is for consent to market any genetically modified higher plant, or schedule 3 in any other case, to the extent that such information is—
(i)
appropriate to the nature and scale of the release or application, and
(ii)
in the case of schedule 2, relevant and necessary for the purposes of the environmental risk assessment referred to in sub-paragraph (c), in view especially of the characteristics of the genetically modified organism and of the scale and conditions of the release or of its intended conditions of use,
(aa)
where the application is for consent to market a genetically modified higher plant, summaries and results of studies referred to in the application for consent to market, including an explanation of their relevance to the environmental risk assessment referred to in sub-paragraph (c), where applicable,
(ab)
where the application is for consent to market a genetically modified higher plant, detailed information on the studies referred to in the application for consent to market, including—
(i)
a description of the methods and materials used or the reference to standardised or internationally recognised methods, and
(ii)
the name of the body or bodies responsible for carrying out the studies,
(b)
information on data or results from any previous release of the same genetically modified organisms, or of the same combination of genetically modified organisms, which has been carried out by the applicant anywhere, and information from any previous application for consent to release the same genetically modified organisms, or the same combination of genetically modified organisms, which the applicant has made to any competent authority of any Member State (including the Scottish Ministers) in accordance with Article 6 of the Deliberate Release Directive or Article 5 of the 1990 Directive;
(c)
an environmental risk assessment prepared in accordance with regulation 6;
(d)
subject to paragraph (4), the information prescribed in Schedule 4;
(e)
the proposed conditions for the marketing of the product, including specific conditions of use and handling;
(f)
a proposed period for the consent which shall not exceed ten years;
(g)
a monitoring plan prepared in accordance with Annex VII of the Deliberate Release Directive which shall include a proposal for the time period of the plan which may differ from the proposed period for the consent;
(h)
a proposal for labelling which shall comply with the requirements laid down in Schedule 4;
(i)
a proposal for packaging; and
(j)
a summary of the application in the format established by the Commission under Articles 13(2)(h) and 30(2) of the Deliberate Release Directive.
(3)
The application may in addition contain–
(a)
data or results from an application for consent to release genetically modified organisms previously made by some other person, provided that if the data or results are confidential a copy of that person’s agreement in writing is contained in the application; and
(b)
any other information which the applicant considers relevant.
(4)
The information provided in accordance with paragraph (2)(a) and (d) shall take into account the diversity of sites of use of the genetically modified organisms and shall include information on any data or results obtained from research and developmental releases concerning the impact of the release on human health and the environment.
(5)
Where the applicant can demonstrate in the application by that person to the satisfaction of the Scottish Ministers that, on the basis of the results of any release in pursuance of and in accordance with a consent for a deliberate release granted by any competent authority of any Member State (including the Scottish Ministers) in accordance with Article 6(5) of the Deliberate Release Directive or Article 6(2) of the 1990 Directive, or on other substantive, reasoned scientific grounds, that the marketing and use of the product consisting of or including the genetically modified organisms do not pose a risk of damage to the environment, the applicant may omit from the application part or all of the information prescribed in Part II of Schedule 4.
Transitional provision in respect of applications to marketF1617.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Transitional measures for adventitious or technically unavoidable presence of genetically modified material which has benefited from a favourable risk evaluation.F1717A.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Applications for renewal of consent to market18.
(1)
Where a consent has been granted under section 111(1) of the Act to market genetically modified organisms which were first marketed in Scotland, any application to renew that consent shall be made in writing to the Scottish Ministers–
(a)
before 17th October 2006 where the consent was granted before the coming into force date of these Regulations; or
(b)
no later than nine months before the expiry of the consent in all other cases.
(2)
The application shall contain–
(a)
a copy of the consent to market the genetically modified organisms;
(b)
where the consent to market was granted–
(i)
after the coming into force date of these Regulations, a report on the results of the monitoring carried out in accordance with the requirements of regulation 28(f); or
(ii)
before that date, a report on the results of any monitoring carried out on the relevant product;
(c)
any other new information which has become available with regard to the risks of the product causing damage to the environment; and
(d)
as appropriate, a proposal for amending, complementing or adding to the conditions of the existing consent, including the conditions concerning future monitoring, and a proposal for the time limitation of the new consent.
(3)
Any consent to market genetically modified organisms first marketed in Scotland which was granted under section 111(1) of the Act before the coming into force date of these Regulations and for which no application for renewal under paragraph (1) has been received by the Scottish Ministers before 17th October 2006 shall be treated as having expired on that date.
(4)
Any consent to market genetically modified organisms marketed in Scotland which was granted under section 111(1) of the Act before the coming into force date of these Regulations and for which an application for renewal under paragraph (1) is refused shall be treated as having expired on 17th October 2006 or the date of refusal of the application, whichever is the later.